KUALA LUMPUR, Nov 8 (Bernama) -- Tessa Therapeutics Limited (Tessa), a clinical-stage cell therapy company has announced the execution of an exclusive agreement with Baylor College of Medicine for worldwide commercial rights to the allogeneic Epstein-Barr virus specific T-cell (EBVST) technology platform.
The platform is jointly developed by Tessa’s Scientific Co-Founder, Malcolm Brenner, M.D., Ph.D., and his colleagues Cliona Rooney Ph.D. and Helen Heslop M.D., D.Sc. at Baylor College of Medicine.
Tessa’s President and Chief Executive Officer, Thomas Willemsen, said in a statement: “Securing exclusive worldwide commercial rights for therapies developed using the EBVST platform is an important value driver for Tessa as we continue to advance TT11X as a potential treatment for CD30-positive lymphomas, while exploring opportunities to extend the technology to other cancer indications, including solid tumours.”
Tessa is currently advancing a pipeline of products that utilise CD30.CAR-modified EBVSTs, including its lead allogeneic cell therapy, TT11X, which is being co-developed for the treatment of relapsed or refractory CD30-positive lymphomas.
Clinical data from an ongoing Phase 1 study of TT11X in CD30-positive lymphomas (BESTA) has demonstrated a favourable safety profile and encouraging signs of efficacy with clinical responses observed in seven of nine patients.
TT11X was recently recognised in the “Most Promising Off-the-Shelf Therapies” category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022.
-- BERNAMA
No comments:
Post a Comment